<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669158</url>
  </required_header>
  <id_info>
    <org_study_id>52212</org_study_id>
    <secondary_id>R21DK111217</secondary_id>
    <nct_id>NCT04669158</nct_id>
  </id_info>
  <brief_title>Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis</brief_title>
  <official_title>A Pilot Study to Treat Adults With Non-Alcoholic Steatohepatitis With Oral Idebenone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled phase 1/2a study to investigate the safety and&#xD;
      tolerability of Idebenone in patients 18 years of age or older with non-alcoholic&#xD;
      steatohepatitis, with stage 1-3 fibrosis. As secondary end point target engagement and&#xD;
      fibrosis improvement will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective phase 1/2a, randomized, double-blinded, placebo-controlled, single&#xD;
      center study of safety and efficacy of oral idebenone in adults 18 years of age or older with&#xD;
      non-alcoholic steatohepatitis (NASH). Following IRB approval and written informed consent, 45&#xD;
      participants will be enrolled in the study and randomized in a 1:2 ratio on REDCap data&#xD;
      capturing software. Participants will be randomized to two groups and receive the following&#xD;
      tablets: placebo, idebenone at escalating doses of 200mg by mouth (P.O.) once a day for 2&#xD;
      weeks, then 200 mg twice a day for 2 weeks, then 3 times per day for the remainder of the&#xD;
      study (up to 48 weeks). Monitoring and safety evaluation will continue for 12 weeks after the&#xD;
      final dose. The study will investigate the safety and tolerability as primary end point and&#xD;
      assess target engagement and fibrosis improvement as secondary end points.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>Week 60: Assessment of AEs</time_frame>
    <description>Number of Participants with Treatment-Related Adverse Events (Assessed by CTCAE v4.0, including abnormal Physical exams and abnormal laboratory tests results will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fibrosis stage</measure>
    <time_frame>Week 48: fibrosis change</time_frame>
    <description>Number of Participants with change in fibrosis stage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Non Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Idebenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take Idebenone 200 mg for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take Placebo for 48 weeks, with study visits in clinic for physical and laboratory assessments at weeks 0, 2, 4, 12, 24, 36, and 48 weeks during treatment period and at 4, and 12 weeks after the last dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone</intervention_name>
    <description>Idebenone, initially 200mg by mouth (P.O.) once a day for 2 weeks, then 200 mg twice a day for 2 weeks, then 200 mg three times per day for the remainder of the study will be used.</description>
    <arm_group_label>Idebenone</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match Idebenone once a day for 2 weeks, then twice a day for 2 weeks, then three times per day for the remainder of the study will be used.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Male or non-pregnant/ non-lactating women ≥ 18 years of age&#xD;
&#xD;
          -  2) Diagnosis of NASH: NAFLD activity score (NAS) of 4 or greater with a score of 1 for&#xD;
             each of the following (steatosis scored 0-3, lobular inflammation scored 0-3,&#xD;
             ballooning scored 0-2):&#xD;
&#xD;
               -  Steatosis&#xD;
&#xD;
               -  Lobular inflammation&#xD;
&#xD;
               -  Hepatocyte ballooning 3) Fibrosis (Ishak fibrosis score ≥1 on liver biopsy)&#xD;
                  within 6 months of enrollment with MELD&lt;10, or based on MRE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any other form of liver disease, including viral hepatitis, autoimmune&#xD;
             hepatitis, alcoholic liver disease, genetic causes of chronic liver disease):&#xD;
&#xD;
          -  Subjects with other etiologies of chronic liver disease, such as chronic hepatitis B&#xD;
             and C; autoimmune hepatitis; and inherited liver disease.&#xD;
&#xD;
          -  ALT&gt;300 U/l&#xD;
&#xD;
          -  Total serum bilirubin ≥ to 1.3 mg/dL (Gilbert's Syndrome patients excepted)&#xD;
&#xD;
          -  International Normalized Ratio (INR) ≥ 1.3&#xD;
&#xD;
          -  MELD&gt;10&#xD;
&#xD;
          -  Serum creatinine &gt;2.0mg/dl&#xD;
&#xD;
          -  Known alcohol abuse or alcohol use disorder:&#xD;
&#xD;
               -  &gt;20 g/day for women&#xD;
&#xD;
               -  &gt;30 g/day for men&#xD;
&#xD;
          -  Active substance abuse&#xD;
&#xD;
          -  Any medical condition that prevents MRE, MR-PDFF&#xD;
&#xD;
          -  Platelet count ≤100//mm3&#xD;
&#xD;
          -  Decompensated cirrhosis&#xD;
&#xD;
          -  Hemoglobin &lt;11 g/dl in females or &lt;12 g/dl in males&#xD;
&#xD;
          -  Presence/history of HCC&#xD;
&#xD;
          -  History of liver transplantation&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
&#xD;
          -  History of inflammatory bowel disease&#xD;
&#xD;
          -  History of cardiovascular disease, long QT syndrome.&#xD;
&#xD;
          -  Subjects who have participated in investigational drug trials and took any&#xD;
             investigational drugs within 60 days prior to the first dose of Idebenone. History of&#xD;
             receiving other investigations drug within 30 days prior to enrollment&#xD;
&#xD;
          -  Any concerns regarding compliance by enrolling physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Torok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie Torok, MD</last_name>
    <phone>6507232188</phone>
    <email>ntorok@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Digestive Health Center, Stanford University</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Smart</last_name>
      <phone>650-725-8517</phone>
    </contact>
    <contact_backup>
      <last_name>Adrian Ekelmans</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalie Torok</last_name>
      <phone>650-723-2188</phone>
      <email>ntorok@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Natalie Torok</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idebenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

